Beta Bionics, Inc. Common Stock (BBNX)

• Market cap: $605M
• 1 day: -6.44%
• 5 days: 19.64%
• 1 month: 18.12%
• 3 months: -38.08%
• 6 months: -40.96%
• Year to date: -40.96%
• 1 year: -40.96%
• 5 years: -40.96%
• 10 years: -40.96%
• Sector: Healthcare
• Industry: Medical Devices

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Employees: 354

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 43% upside
• Avg. target: $27 91% upside
• High target: $31 122% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

Stifel Mathew Blackman 44% 1-year accuracy 7 / 16 met price target	79% upside $25	Buy Initiated	24 Feb 2025
Lake Street Brooks O'Neil 27% 1-year accuracy 4 / 15 met price target	115% upside $30	Buy Initiated	24 Feb 2025
Piper Sandler Matt O'Brien 48% 1-year accuracy 24 / 50 met price target	86% upside $26	Overweight Initiated	24 Feb 2025
Leerink Partners Mike Kratky 50% 1-year accuracy 2 / 4 met price target	101% upside $28	Outperform Initiated	24 Feb 2025
Ladenburg Thalmann Jeff Cohen 40% 1-year accuracy 2 / 5 met price target	122% upside $31	Buy Initiated	20 Feb 2025